Jeevan Therapeutics has achieved an important milestone in the development of its next-generation bispecific nanobody therapeutic program for Crohn's disease.
Our bispecific nanobody constructs have been successfully produced, marking an important step forward in the development of our lead program.
Our lead program is designed to address two complementary biological mechanisms involved in Crohn's disease persistence and relapse.
With our bispecific constructs now produced, we are advancing functional characterization and optimization to evaluate their biological activity and identify promising candidates for further development.
These efforts build on our earlier discovery and blocking studies and represent another step toward selecting a development candidate.
Our immediate priorities include functional validation, lead optimization, and developability assessments.
These studies will inform candidate selection and preparation for in vivo proof-of-concept studies, an important next milestone in our development strategy.
Jeevan is developing a differentiated bispecific nanobody therapeutic designed to address complementary mechanisms involved in inflammatory immune-cell trafficking and tissue retention.
By targeting both mechanisms within a single molecule, we aim to address important contributors to disease persistence and relapse, with the long-term goal of achieving deeper and more durable remission for people living with Crohn's disease.
Advancing a new approach to durable remission.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.